Amsterdam Life Sciences Café: Biotechbooster and Neogene

The Amsterdam Economic Board and EY welcome you to the next Amsterdam Life Sciences Café on 4 Octobre 2022

This edition will be focussed on the innovative work by Biotechbooster and Neogene.

It promises to be an exciting get together again, with an extra warm welcome to those Life Sciences companies looking to make a next step.

• Davide Iannuzzi (Chief Impact Officer, VU) will talk about the Biotech booster programma, which has been awarded a grant of 250 million euros from the National Growth Fund. The aim of this investment is for research to turn into concrete products faster, better and more often – in other words, valorisation. And that will have an enormous impact on our society.

• Sanne Weijzen (VP Corporate Strategy, Neogene Therapeutics) talks about Neogene, a global, preclinical stage biotechnology company pioneering the development of next generation, fully individualized engineered T cell therapies for a broad spectrum of cancers. Our proprietary neoantigen T cell receptor (TCR) discovery and T cell engineering platform identifies TCR genes with specificity for neoantigens – found exclusively on cancer cells as a result of cancer-associated DNA mutations.  Neogene’s novel approach delivers a tailored T cell therapy containing a unique set of specific TCR genes for each individual patient.

As always, we will start with a brief update on Life Sciences in the region and we will make sure there is ample time for discussion – right after the presentations and during drinks.

Walk-in: 3.30 PM, Start: 4.00 PM

The Café’s feature presentations and debates. A great opportunity to meet and mingle with colleagues from the life sciences sector and representatives from the broader business community in Amsterdam. If you have any feedback, ideas or extra information that may influence future editions of the Life Sciences Café, please contact Gerty Holla.

Host or Publisher Amsterdam Economic Board i.s.m. EY